INCREASING THE INFORMATION CONTENT OF A COMMERCIAL TISSUE OXIMETER

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 及早认识到严重出血是减少战场侮辱造成的死亡率和发病率的关键因素。尽管近红外(NIR)仪器在识别出血方面显示出了希望，但必须解决特定的混杂因素才能可靠地诊断早期出血。我们的假设是，这些混杂因素可以通过适当的光-组织相互作用建模(频域光子迁移)以及增加光谱(1000个波长)和时间(200ms)带宽来消除。这项提议的目的是提供一种紧凑的护理点近红外仪器，能够定量检测早期出血并监测治疗干预。我们的建议以以下合作为特色：(1)一家领先的生物医学技术公司(ISS公司，伊利诺伊州香槟)，生产最先进的近红外组织血氧仪，运营生产设施，并具有FDA提交经验；(2)一个大学研究团队(加州大学欧文分校贝克曼激光研究所)，组织光学专家，他们有通过近红外光学方法评估创伤损伤的经验。将对现有的ISS血氧仪进行改装，以增加信息含量，以解决混淆因素。在第一阶段结束时，我们将提供一种独特的近红外仪器，可用于全面验证和优化研究(第二阶段)和随后的商业小型化(第三阶段)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The early recognition of severe hemorrhage is a key factor towards reducing mortality and morbidity from battlefield insults. Although near-infrared (NIR) instruments have shown promise in recognizing hemorrhage, specific confounding factors must be solved to be reliable in early hemorrhage. Our hypothesis is that these confounding factors can be eliminated by proper light-tissue interaction modeling (frequency-domain photon migration), and by increasing spectral (1000 wavelengths) and temporal (200 ms) bandwidth. The objective of this proposal is to provide a compact point-of-care NIR instrument that is capable of quantitatively detecting early hemorrhage and monitoring therapeutic interventions. Our proposal features collaboration between (1) a leading biomedical technology company (ISS, Inc., Champaign, IL) that produces state-of-the-art NIR tissue oximeters, operates production facilities and has FDA submission experience, and (2) a university research team (Beckman Laser Institute, UC Irvine), with tissue optics experts who have experience in the assessment of traumatic injury via NIR optical methods. The existing ISS oximeter will be modified to increase information content that will solve the confounding factors. At the conclusion of Phase I, we will provide a unique NIR instrument that will be available for comprehensive validation and optimization studies (Phase II) and subsequent commercial miniaturization (Phase III).